Monday Memo  

Weekly update from...
Athena Forum logo

Monday, February 17, 2014
  Clinical Accuracy Spoken Here  

Multiple Sclerosis: Monitor for Adherence

Patients with MS need to develop realistic expectations. Sadly, therapies will not cure MS, but can reduce the frequency and severity of relapsing episodes and slow disease progression. Some therapies have side effects, but those can be managed.
Patients should be alert for the adverse reactions that may occur, including:

  • Depression, suicide
  • Injection site necrosis
  • Allergic reactions
MS treatment will have a continued high cost. The Case Manager will need to work closely with the treatment team in coordinating the appropriate scheduling of tests, and that patient's adherence is well monitored.

[Reference: MS, Module D, CM Role in MS Care]

  Excellence in Case Mgmt  

Multiple Sclerosis:
CM - The Intervention That
Improves Adherence

Case Management is the intervention that improves adherence. CMs empower patients to receive necessary and desired care focusing on patient's desired outcomes. Keeping patients adherent saves money, decreases hospitalization, use of home care and other services. Case Managers can assume a pivotal role in continuity of care related to adherence. CMs can facilitate, encourage, educate, inform, assure patient access to the right information, track down and piece together patient's history from previous providers, advocate and evaluate plans of treatment. It is the Case Manager's role to ensure patient adherence.

[Reference: MS, Module D, CM Role in MS Care]

  Improving Patient Care...  

Multiple Sclerosis: Oral Option Influences Adherence

Fingolimod represents a new class of MS therapy. It is the first medication to be taken orally rather than by injection or infusion. The ease of having this option available may significantly heighten MS patients' success in embarking upon and adhering to therapy.

The second distinction is Fingolimod binds to a docking site on immune cells (T cells and B cells) implicated in causing nervous system damage in MS. The drug appears to force immune cells to remain in lymph nodes, and inhibits them from migrating.

Fingolimod is approved for the treatment of adults with relapsing forms of MS.

[Reference: MS Course, Welcome Page]


Tom RasmussenTom Rasmussen
Athena Forum


NEW courses in Development

» Ethics in Case Management
» Breast Cancer Care
» Improving Outcomes in ESRD



Cathy WrightCathy Wright, BSN, RN
Clinical Editor
Athena Forum




Online CE for RN, CCM & LSW
4,000 pages of clinical excellence.

Clinical Excellence® Series
» Asthma
» Behavioral Health
» Colorectal Cancer
» CV Risk: Stroke & MI
» Diabetes
» EOL & Palliative Care
» GI Disorders
» Heart Failure
» Multiple Sclerosis
» Obesity Management
» Pain Management
» Rheumatoid Arthritis
» Sepsis Care
» Women's Health
» Wound Care & Payments

CM Excellence® Series

» CM Express®
» Discharge Planning
» Hospital Revenue Cycle
» Patient Advocacy
» Population Health
» Principles of Hospital CM
» Professional Identity
» Utilization Management



Athena Forum Help Desk
Mon-Fri 9am-5pm ET

Recommend to a friend
Tom Rasmussen, Publisher

Enrollment & passwords
Janice Graham, Registrar

  Monday Memo Archives
Did you miss an issue? Need to look up a reference in a past Monday Memo? All past issues are archived for your use. Click here.

Athena Forum, LLC awards CE for ANCC - NASW - CCMC

Athena Forum is a world wide service mark in nursing education
by the U.S. Office of Trademarks and Patents.

Copyright 2012 All rights reserved | Headquarters in Boca Raton, FL | 800-583-2506 | www.athenaforum.com